AbbVie
Biopharmaceuticals · United States
AbbVie discovers, makes and sells prescription medicines and aesthetics products for immune, brain, cancer and eye conditions, led by Skyrizi and Rinvoq.
What makes it different
Two newer drugs now outsell its former best-seller.
$17.6BSkyrizi net revenuesFY2025
Skyrizi and Rinvoq took over as Humira faced biosimilar competition in the United States.
How big it is
How big is AbbVie?
$61.2BNet revenuesFY2025
57,000Employees2025
$9.1BR&D expenseFY2025
How it makes money FY2025
Immunology brings in half of revenue.
- Immunology50%$30.4B
- Neuroscience18%$10.8B
- Oncology11%$6.7B
- Aesthetics8%$4.9B
- Other14%
How the business works
Buy pipelines. Launch drugs. Sell via wholesalers.
- 1Companies and late-stage pipelines
- 2Immunology and neuroscience drugs
- 3Through three US wholesalers
Purchased companies such as Allergan and ImmunoGen supply many of today's growth products.
Who owns it
- The Vanguard Group10.02%
- BlackRock, Inc.8.09%
CEO: Robert A. Michael
Who it competes with
Key moments
- 1-01Spun off from Abbott
- 5-26Acquires Pharmacyclics
- 9-04Skyrizi approved by the FDA
- 9-08Rinvoq approved by the FDA
- 5-08Completes Allergan acquisition
Sources
Every number on this page comes from AbbVie's own reports.
Full profile
The rest of the story is in the app.
What AbbVie tracks23 metrics
R&D ratio
Employees
Products above $1B
Results, quarter by quarterwith a chart
Revenue
Profit
Margin
Where the money comes from2 regions
United States
International
The full timeline21 moments
2024
2025
2026
AbbVie vs Johnson & Johnsonside by side
Revenue
Profit
People
Point your phone at a logo.
See the company behind it.
The full story in 12 chapters · compare any two companies · 335 companies, and any other on request.
Download on the App Store
